17:52 , Aug 29, 2018 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Sepsis Cell culture and mouse studies identified a GSDMD inhibitor that could help treat sepsis. In vitro, the previously identified necroptosis inhibitor necrosulfamide bound GSDMD with a Kd of 32 μM. In mouse bone...
18:36 , Aug 23, 2018 |  BC Innovations  |  Emerging Company Profile

Bugs on film

Microbiome company Scioto Biosciences Inc. is turning a longstanding enemy of antibiotics developers -- biofilms -- into a delivery vehicle for probiotics. The company expects its lead candidate SB-121, an orally delivered biofilm formulation of Lactobacillus...
17:16 , Aug 3, 2018 |  BC Week In Review  |  Clinical News

Sienna's acne photoparticle therapy misses in two pivotal trials

Sienna Biopharmaceuticals Inc. (NASDAQ:SNNA) said SNA-001 missed the primary and secondary endpoints in a pair of pivotal trials to treat moderate to severe acne vulgaris. The candidate is a topical photoparticle therapy targeting the sebaceous gland...
18:27 , Mar 30, 2018 |  BC Week In Review  |  Company News

ICER issues final evidence report on CAR T therapies with policy recommendations

After the Institute for Clinical and Economic Review's California Technology Assessment Forum held a public meeting to discuss the comparative effectiveness and value of CAR T therapies, the institute released a final evidence report with...
00:43 , Mar 3, 2018 |  BioCentury  |  Finance

Rocky road

While a trio of buysiders who spoke with BioCentury believe sentiment toward Celgene Corp. will remain poor in the near term in the wake of a regulatory delay for ozanimod, they believe commercial success from...
00:06 , Mar 3, 2018 |  BC Extra  |  Politics & Policy

Senator questions pharmas on use of tax savings

Sen. Tina Smith (D-Minn.) sent letters to the CEOs of five large U.S. pharmas on Thursday questioning how they have been using their corporate tax savings since the passage of the Tax Cuts and Jobs...
20:46 , Feb 16, 2018 |  BC Week In Review  |  Clinical News

Priority Review for Agios' ivosidenib

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) said FDA accepted and granted Priority Review to an NDA for ivosidenib (AG-120) to treat relapsed or refractory acute myelogenous leukemia (AML) in patients with an isocitrate dehydrogenase 1 (IDH1) mutation....
19:38 , Feb 16, 2018 |  BC Week In Review  |  Clinical News

FDA approves Banyan's brain trauma blood test

FDA approved the Banyan Brain Trauma Indicator (BTI) from Banyan Biomarkers Inc. (Alachua, Fla.) as an in vitro diagnostic blood test to aid in the evaluation of adults with suspected mild traumatic brain injury (TBI)....
19:45 , Feb 15, 2018 |  BC Extra  |  Company News

Priority Review for Agios' ivosidenib

Agios Pharmaceuticals Inc. (NASDAQ:AGIO) said FDA accepted and granted Priority Review to an NDA for ivosidenib (AG-120) to treat relapsed or refractory acute myelogenous leukemia (AML) in patients with an isocitrate dehydrogenase 1 (IDH1) mutation....
22:50 , Jan 19, 2018 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck At least seven profitable biotechs and pharmas are slated to report earnings this week. (A) Premarket on U.S. exchanges, during trading hours in Europe; (B) Fiscal 3Q CompanyDatePre/post mkt4Q17 EPS est4Q16 EPSExpected chgJohnson &...